Starpharma (ASX:SPL) share price tanks 3% on 67% revenue drop

Starpharma shares are taking today…

| More on:
share price dropping

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Starpharma Holdings Limited (ASX: SPL) share price has dropped 2.76% this Thursday as the pharmaceutical company reported its earnings for the financial year ended 30 June 2021 (FY2021).

Starpharma share price slumps as revenues fall, losses mount

  • Revenues from continuing operations of $2.15 million, down 67% compared to the prior corresponding period of FY2020 (pcp)
  • Total revenues and other income of $3.5 million, down 50.7% from pcp
  • Loss after tax of $19.73 million, an increase of 34% over the pcp's loss of $14.7 million
  • No final dividend was declared for FY2021

What happened in FY21 for Starpharma?

The financial year just passed was a wild one for Starpharma, as evidenced by the company's share price range over the past year. With a 52-week high of $2.51 a share and a low of $1.12, investors have certainly been erratic at valuing this company's shares.

Back in February, investors lit a rocket under Starpharma shares when it announced that its Viraleze nasal spray, which has antiviral applications, gained successful registration for sale in Europe. That included the United Kingdom (UK). This news seemed to be the driving force behind Starpharma reaching its new all-time high in February. However, since then, the road has been rockier.

In June, the company took a bit of a hit. The UK Medicines and Healthcare Products Regulatory Agency pinged Starpharma for "allowable promotional claims" promoting Viraleze as a potential preventative measure against COVID-19 infection. The Starpharma share price fell around 10% at the time.

However, last month, the shares once again got a boost when Starpharma announced that Viraleze "has potent virucidal activity against the Delta variant of COVID-19".

What did management say?

Here's some of what Starpharma CEO Dr Jackie Fairley had to say on Starpharma's FY21 numbers today:

2021 has been a remarkable year for all of us around the world. Despite the impact of the unrelenting global pandemic, Starpharma was able to continue to recruit into our three DEP phase 2 clinical programs and achieve a number of important commercial milestones across the business. These included the rapid development and launch of VIRALEZE… 

The company is extremely proud to have developed, registered and launched VIRALEZE ahead of schedule and in time for it to play a role in the evolving situation in Europe.

What's next for Starpharma?

Dr Fairley also stated that the year ahead will see Starpharma focus on its DEP drug delivery platform. As well as  progressing "further registrations, distribution arrangements and launches for VIRALEZE in other regions". It will also aim for further registrations and launches of its VivaGel product.

Although the Starpharma share price is down more than 3% today, the company's losses for 2021 so far are now sitting at 19.8% year to date. The company is also down around 7.15% over the past 12 months. At the current Starpharma share price of $1.24, the company has a market capitalisation of $501.51 million.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Earnings Results

A woman looks up at a plane flying in the sky with arms outstretched as the Flight Centre share price surges
Earnings Results

Web Travel share price rockets 13% on market leading full-year growth

Investors are sending Web Travel shares soaring today. Here’s why.

Read more »

Happy shopper at a clothes shop.
Earnings Results

Why did Myer shares just rocket 9%?

Investors are piling into Myer shares on Friday. But why?

Read more »

A woman looks up at a plane flying in the sky with arms outstretched as the Flight Centre share price surges
Earnings Results

Up 78% since April, why is the Webjet share price taking off again today?

Webjet shares have soared 78% since 4 April and are lifting off again today. But why?

Read more »

a woman holds her hands to her temples as she sits in front of a computer screen with a concerned look on her face.
Industrials Shares

Guess which ASX 200 stock is crashing 24% on results day

Investors were not impressed with this result. But why?

Read more »

A man in full American NFL playing kit crouches over with his arms across his chest in a defensive stance against a dark background.
Technology Shares

ASX 300 tech stock charges 7% higher to record high on stellar results

This tech stock delivered another impressive result this morning.

Read more »

a group of people sit around a computer in an office environment.
Earnings Results

Guess which ASX 200 tech stock is rocketing 12% on record results

Another half, another record result from this high-quality company.

Read more »

A young man sitting at an outside table uses a card to pay for his online shopping.
Consumer Staples & Discretionary Shares

Why is the Kogan share price crashing 12%?

Profits are down at this ecommerce company during the second half.

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Resources Shares

Guess which ASX 200 mining stock is sinking 7% following its quarterly update

Let's see how this miner performed during the third quarter.

Read more »